Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer

Table 3 Incidence of adverse events attributable to abiraterone in the pre- and post-chemotherapy settings

Adverse events	Pre-chemotherapyincidence (95%CI)	Post-chemotherapyincidence (95%CI)
Cardiac disorders all-grade	3.0% (1.9%-4.8%)	4.0% (2.8%-5.6%)
Fluid retention and edema all-grade	4.0% (2.6%-6.0%)	9.0% (7.2%-11.2%)b
Hypertension all-grade	9.0% (6.9%-11.7%)	3.0% (2.0%-4.4%)b
Hypokalemia all-grade	9.0% (7.2%-11.2%)	4.0% (2.6%-6.0%)b
Hypokalemia high-grade	0.1% (1.0%-1.5%)	3.7% (2.6%-5.2%)b

^bP < 0.01, pre-chemotherapy vs post-chemotherapyincidence. The incidence rate attributable to abiraterone = incidence rate of abiraterone and prednisone minus that of placebo and prednisone.